Somatic inactivation of the TP53 gene in breast tumors is a marker for poor outcome, and breast cancer outcome might also be affected by germ-line variation in the TP53 gene or its regulators. We investigated the effects of the germ-line single nucleotide polymorphisms TP53 R72P (215G>C) and MDM2 SNP309 (-410T>G), and p53 protein expression in breast tumors on survival.
Methods
We pooled data from four breast cancer cohorts within the Breast Cancer Association Consortium for which both TP53 R72P and MDM2 SNP309 were genotyped and follow-up was available (n = 3,749). Overall and breast cancer-specific survival analyses were performed using Kaplan-Meier analysis and multivariate Cox's proportional hazards regression models.
Results
Survival of patients did not differ by carriership of either germ-line variant, R72P (215G>C) or SNP309 (-410G>T) alone. Immunohistochemical p53 staining of the tumor was available for two cohorts (n = 1,109 patients). Survival was worse in patients with p53-positive tumors (n = 301) compared to patients with p53-negative tumors (n = 808); breast cancer-specific survival: HR 1.6 (95% CI 1.2 to 2.1), P = 0.001. Within the patient group with p53-negative tumors, TP53 rare homozygous (CC) carriers had a worse survival than G-allele (GG/GC) carriers; actuarial breast cancer-specific survival 71% versus 80%, P = 0.07; HR 1.8 (1.1 to 3.1), P = 0.03. We also found a differential effect of combinations of the two germ-line variants on overall survival; homozygous carriers of the G-allele in MDM2 had worse survival only within the group of TP53 C-allele carriers; actuarial overall survival (GG versus TT/TG) 64% versus 75%, P = 0.001; HR (GG versus TT) 1.5 (1.1 to 2.0), P = 0.01. We found no evidence for a differential effect of MDM2 SNP309 by p53 protein expression on survival.
Conclusions
The TP53 R72P variant may be an independent predictor for survival of patients with p53-negative tumors. The combined effect of TP53 R72P and MDM2 SNP309 on survival is in line with our a priori biologically-supported hypothesis, that is, the role of enhanced DNA repair function of the TP53 Pro-variant, combined with increased expression of the Mdm2 protein, and thus overall attenuation of the p53 pathway in the tumor cells.
Introduction
Breast cancer outcome may be affected by germ-line variants in genes that play a role in DNA damage control and repair such as TP53 (R72P) and MDM2 (SNP309) [1, 2]. The Mdm2 protein is a negative regulator of the tumor suppressor protein p53 [3]. The R72P (215G>C) polymorphism of the TP53 gene is located in a proline-rich region of p53 suggested to be required for the growth suppression activity of p53 [4] and for its ability to induce apoptosis [5]. The two variant protein forms, R72 (arginine) and 72P (proline), have been shown to differ in their biological functions: the R72 variant is a stronger and faster inducer of apoptosis than the 72P variant [6, 7]. The 72P variant also binds more efficiently to iASPP, an inhibitor of pro-apoptotic function of p53, which may be another reason for the inferiority in apoptosis induction of this variant [8]. The 72P variant has been found to be more efficient in inducing cell-cycle arrest [7] and DNA repair [9] than the R72 variant which may protect tumor from chemotherapy-induced apoptosis.
Previous studies have shown that the R72P polymorphism is not associated with increased breast cancer risk [1, 10, 11]. However, an association of R72P with breast cancer survival has been suggested, though with inconsistent results and possibly only in patients with p53-negative tumors [10–16]. It has also been suggested that patients with the Pro/Pro genotype are less sensitive to anthracycline-based treatment than those with the Arg/Pro or Arg/Arg genotype [14, 16], in line with the Pro-allele being more efficient in cell-cycle arrest [7] and DNA repair [9] induction.
A common single nucleotide polymorphism in the MDM2 promoter region, a T to G change at nucleotide 309 in the first intron (-410G>T; named SNP309), has been shown to create an improved Sp1 binding site, leading to increased expression of the Mdm2 protein and thus attenuation of the p53 pathway and accelerated tumor formation in individuals carrying a germ-line p53 mutation [17–19]. A number of small studies revealed an inconsistent association between SNP309 and breast cancer risk (see overview in [1], and [20, 21]). However, we have shown in a large pooled analyses of the Breast Cancer Association Consortium series that there is no general association of SNP309 with breast cancer, nor if stratified by estrogen receptor (ER) [1].
In two small studies no association between breast cancer survival and MDM2 SNP309 genotype alone was found [13, 22]. However, the results of one of those studies suggested a differential effect of MDM2 SNP309 genotype by tumor p53 status (mutant p53 or aberrant protein expression) on breast cancer survival [22]. Though MDM2 SNP309 has been implicated to affect survival in other tumors (for example, [23]), as far as we know there are no other publications on breast cancer outcome and this polymorphism, except for a recent publication in BRCA1/2 carriers of Ashkenazi origin [24]. Our aim was to investigate the combined effects of MDM2 SNP309 and TP53 R72P polymorphisms and p53 protein expression on breast cancer survival.
Materials and methods
Clinico-pathologic data and genotyping
Breast cancer cases from four European studies within the Breast Cancer Association Consortium were included in this analysis (Table 1) [1, 25]. Patients that were genotyped for MDM2 SNP309 and TP53 R72P from studies with follow-up data were included [1]. Patient selection criteria, participation rates and information on the collection of follow-up and clinical data are shown in Table 1. P53 protein expression data were available for two of the four studies (Table 1). Immunohistochemical staining of TMA slides was performed with a mouse monoclonal anti-human p53-antibody (DO-7, DAKO) (Table 1). Missing p53 data could be attributed to missing tumor blocks, loss of cores in the slicing or staining process or cores not containing enough tumor material. P53 protein expression scoring and MDM2 SNP309 and TP53 R72P genotyping were performed blinded to the survival status of the patients. Genotyping assays were performed by each group separately [1] (see Table 1 for assay description). Primer (and probe) sequences are available from the authors upon request. Methods and results in this paper are reported following the REMARK recommendations [26]. All studies were approved by the appropriate (Medical) Ethical Research Committees.
Table 1
Characteristics of the studies and genotyping assays
ABCS: Amsterdam Breast Cancer Study, The Netherlands [41]
Hospital-based consecutive cases
All operable breast cancer patients aged < 50 years diagnosed 1974-1994 in four Dutch hospitals (Amsterdam and Leiden) (23 to 50 years)
All patients with paraffin-embedded tissue blocks available (normal tissue) from the Pathology archives and successful DNA isolation (approximately 85%)
Active follow-up through the medical registries and general practitioners
By IHC staining of TMAs* as previously described [25]; p53 positive defined as > 10% of cells with positive nuclear staining.
Taqman
HABCS: Germany:
Hannover Breast Cancer Study and bilateral breast cancer patients [42, 43]
Hospital-based case-control studies
Case patients who received radiotherapy for breast cancer at Hannover Medical School between 1997 and 2003 (27 to 91 years)
Approximately 80% of case subjects contacted agreed to give a blood sample
Active follow-up at the Department of Radiation Oncology, Hannover Medical School
Consecutive incident cases from the Department of Oncology, Helsinki University Central Hospital 1997-1998
(22 to 96 years)
79% of the case subjects
Active follow-up of the medical records until five years and annual linkage to the nation-wide Finnish Cancer Registry
By IHC staining of TMAs* as previously described [10] and data for 23 cases derived from the pathology reports; p53 positive defined as > 20% of cells with positive nuclear staining.
SEARCH: Studies of Epidemiology and Risk Factors in Cancer Heredity, Cambridge, UK [45]
Population-based case-control study
Two groups of case patients (prevalent and incident) identified through East Anglian Cancer Registry: patients diagnosed before age 55 years in 1991 to 1996 and still alive when study started in 1996 and patients diagnosed before age 70 years since 1996 (25 to 65 years)
64% of eligible case subjects provided a blood sample
Combination of passive follow-up through national death registrations and active follow up every five years by the cancer registry
NA
Taqman
*IHC = immunohistochemistry; TMA = Tissue Micro Array; NA = not applicable (no p53 data available).
Statistical analyses
Univariate analyses of survival were performed by calculating Kaplan-Meier survival curves and comparing subsets of patients using log-rank test. To explore the effects of several variables and their combined effects on survival, multivariate Cox's proportional hazards regression models were used (reported as Hazard Ratio (HR) with 95% confidence interval). Results are reported for one polymorphisms stratified by the other polymorphisms or p53 expression, adjusted for other covariates. Interaction terms were tested by Cox regression models including the main effects (2df each), interaction terms, for example, four interaction terms for both polymorphisms, and other covariates. Covariates included were prognostic factors for breast cancer survival, that is, age, stage, grade and ER and p53 protein expression. In order to run models including all patients, missing value categories were included for each separate variable with missing information. Polymorphisms were included as categorical variables (with the homozygous common allele group as reference), or as a continuous variable in the per-allele analyses. All pooled analyses were adjusted for study, that is, ABCS, HABCS, HEBCS, SEARCH, included as a categorical variable. Breast cancer-specific survival was defined as survival until death from breast cancer, with breast cancer being the underlying cause of death; death due to other causes was censored (these analyses included the ABCS and HEBCS studies, see Table 1). Overall survival was defined as survival until death of any cause. In all analyses, follow-up time was censored at 10 years. All statistical tests used were two-sided and P values < 0.05 were considered statistically significant. All analyses were performed using SPSS 15.0 (SPSS Inc, Chicago, IL, USA).
Results
Patient characteristics
Breast cancer patients with follow-up and TP53 R72P and MDM2 SNP309 genotypes from three hospital-based and one population-based study within the Breast Cancer Association Consortium were included for analysis (n = 3,749) (Table 1). Frequencies of TP53 R72P and MDM2 SNP309 and clinicopathologic characteristics of the breast cancer patients in the four studies are shown in Table 2. We have described and discussed earlier the small difference in MDM2 SNP309 allele frequencies between European populations [1] while difference in patient characteristics between studies can mostly be attributed to differences in patient selection criteria (Table 1). Mean follow-up was 7.7 years (SD 4). A small number patients (n = 26) were carriers of the homozygous rare variants for both polymorphisms (Table 3).
Table 2
Germ-line variants and clinicopathologic characteristics of breast cancer patients by study
ABCS
N = 1076
HABCS
N = 152
HEBCS
N = 599
SEARCH
N = 1922
P value*
N
%
N
%
N
%
N
%
MDM2SNP309
TT
444
41.3
55
36.2
183
30.6
774
40.3
GT
487
45.3
73
48.0
311
51.9
913
47.5
GG
145
13.5
24
15.8
105
17.5
235
12.2
< 0.001
TP53R72P
GG
570
53.0
85
55.9
314
52.4
1052
54.7
GC
422
39.2
55
36.2
236
39.4
733
38.1
CC
84
7.8
12
7.9
49
8.2
137
7.1
0.9
Stage
1
341
31.9
83
69.2
205
36.9
861
52.4
2
581
54.4
36
30.0
295
53.1
713
43.4
3
146
13.7
1
0.8
56
10.1
69
4.2
< 0.001
Missing
8
32
43
279
Differentiation grade
1
338
35.8
9
8.7
138
24.6
368
25.4
2
317
33.6
55
53.4
243
43.2
647
44.7
3
288
30.5
39
37.9
181
32.2
431
29.8
< 0.001
Missing
133
49
37
476
ER status tumor
Negative
240
34.2
18
15.4
135
23.2
175
19.8
Positive
461
65.8
99
84.6
446
76.8
708
80.2
< 0.001
Missing
375
35
18
1039
p53 status tumor
Negative
473
70.4
335
76.7
Positive
199
29.6
102
23.3
0.02
Missing
404
152
162
1922
Vital status patient
Alive
694
64.5
129
84.9
462
77.1
1596
83.0
Deceased, all
382
35.5
23
15.1
137
22.9
326
17.0
< 0.001
Deceased, breast cancer
337
20
105
Years of diagnosis
Range
1974 to 1994
1997 to 2003
1997 to 1998
1991 to 1996
Age at diagnosis
Mean ± SD
42.8
5.2
56.8
11.3
56.4
12.8
50.1
7.7
< 0.001
Follow-up
Mean ± SD
10.5
5.7
6.5
1.9
7.3
2.1
6.3
2.1
< 0.001
* P value of comparison of either categories of non-missing data among studies (by chi-square) or comparison of continuous data (by t-test).
Table 3
Frequencies of TP53 R72P and MDM2 SNP309 germ-line variants
TP53R72P
GG
GC
CC
N
%
N
%
N
%
MDM2SNP309 TT
799
54.9
546
37.5
111
7.6
GT
940
52.7
699
39.2
145
8.1
GG
282
55.4
201
39.5
26
5.1
Breast cancer survival by TP53 R72P, MDM2 SNP309 genotype, and p53 tumor status
Overall survival of patients did not differ by carriership of either germ-line variant, R72P or SNP309, alone in the pooled analyses (Table 4). Tumor p53 status was available for 1109 patients from the ABCS and HEBCS series (Table 1). In both series, the patients with p53-positive tumors showed poorer overall survival than the patients with p53-negative tumors (pooled HR 1.5 (1.2-1.9), P = 0.002; Table 4).
Table 4
HR estimates of overall survival* by TP53 R72P, MDM2 SNP309 and p53
TP53R72P**
HR
Lower and upper limit 95% CI
Pvalue
ABCS
GC
0.99
0.79
1.26
0.95
CC
0.72
0.45
1.16
0.17
HABCS
GC
1.40
0.60
3.45
0.46
CC
2.54
0.69
9.34
0.16
HEBCS
GC
1.17
0.82
1.67
0.40
CC
1.72
1.00
2.98
0.05
SEARCH
GC
1.18
0.95
1.49
0.14
CC
0.93
0.59
1.48
0.77
Pooled†
GC
1.11
0.96
1.28
0.18
CC
1.00
0.76
1.31
0.97
MDM2SNP309**
ABCS
TG
0.93
0.73
1.18
0.54
GG
0.99
0.70
1.40
0.97
HABCS
TG
0.60
0.25
1.46
0.26
GG
0.36
0.08
1.65
0.19
HEBCS
TG
0.76
0.53
1.11
0.16
GG
0.91
0.56
1.47
0.69
SEARCH
TG
1.03
0.82
1.31
0.78
GG
1.43
1.03
1.97
0.03
Pooled†
TG
0.93
0.80
1.08
0.34
GG
1.11
0.90
1.37
0.31
p53 status tumor **
ABCS
p53 positive
1.31
0.96
1.80
0.09
HEBCS
p53 positive
1.93
1.27
2.94
0.002
Pooled†
p53 positive
1.50
1.16
1.93
0.002
Breast cancer-specific survival
Pooled†
p53 positive
1.57
1.20
2.05
0.001
*Overall survival including all studies unless otherwise specified; ** HRs of heterozygous and homozygous rare allele groups have been calculated by comparison to the reference categories of common alleles: TP53 R72P = GG; MDM2 SNP309 = TT; p53 = negative tumors; †Pooled analyses have been adjusted for study.
Differential effect of TP53 R72P on breast cancer survival stratified for p53 tumor status
In the patient group with p53-negative tumors, the actuarial breast cancer-specific survival for the patients carrying the TP53 CC genotype (Pro/Pro) was worse, though not statistically significantly, at 10 years of follow-up as compared to those carrying TP53 GG/GC (Arg/Arg; Arg/Pro) (71% versus 80% P = 0.07; Figure 1). The interaction terms between p53 expression and TP53 R72P were not significant in a multivariate Cox regression analysis, but considering the difference seen in the actuarial curves we still considered it useful to perform Cox analyses stratified for p53 expression. Patients with the TP53 CC genotype had worse breast-cancer specific survival (HR adjusted for study, age, stage, grade and ER: 1.79 (1.05 to 3.05, P = 0.03) (Table 5). Results for overall survival were in line with those of breast-cancer specific survival, but did not reach statistical significance (P = 0.06, Table 5).
Figure 1
Cumulative breast cancer-specific survival (Kaplan Meier) of breast cancer patients with p53 negative tumors stratified by TP53 R72P. Survival in the TP53 CC group was worse compared to that in the GC and GG group combined (80% versus 71%, P = 0.07).
Table 5
HR estimates of overall and breast cancer-specific survival by TP53 R72P, in p53 negative and positive tumors (multivariate models)
TP53R72P
HR
Lower and upper limit 95% CI
P value
Overall survival
p53 negative tumors
GC
1.11
0.80
1.52
0.54
CC
1.63
0.97
2.74
0.06
p53 positive tumors
GC
0.82
0.53
1.27
0.37
CC
0.86
0.34
2.18
0.75
Breast cancer-specific survival
p53 negative tumors
GC
0.97
0.68
1.37
0.85
CC
1.79
1.05
3.05
0.03
p53 positive tumors
GC
0.90
0.57
1.42
0.65
CC
1.00
0.39
2.55
1.00
MDM2 SNP309
HR
Lower and upper limit 95% CI
Pvalue
Overall survival
p53 negative tumors
TG
0.84
0.60
1.17
0.30
GG
1.28
0.85
1.94
0.24
p53 positive tumors
TG
0.78
0.49
1.24
0.30
GG
0.78
0.41
1.48
0.45
Breast cancer-specific survival
p53 negative tumors
TG
0.92
0.64
1.31
0.63
GG
1.41
0.90
2.19
0.13
p53 positive tumors
TG
0.76
0.47
1.23
0.27
GG
0.69
0.35
1.39
0.30
Pooled analyses for studies with p53 information (ABCS and HEBCS); HRs of heterozygous and homozygous rare allele groups have been calculated by comparison to the reference categories of the homozygous common allele: TP53 R72P = GG, and MDM2 SNP309 = TT; analyses have been adjusted for study, age, stage, grade and ER.
Within the patient group with p53-positive tumors, breast cancer-specific survival stratified by TP53 R72P seemed to show inconsistent results between studies though none were significant, that is, per allele HR (adjusted for age, stage, grade and ER) in the ABCS study was 0.74 (0.45 to 1.22) and in the HEBCS study 1.46 (0.79 to 2.69). The pooled HR (adjusted for study, age, stage, grade and ER) was 0.82 (0.53 to 1.27) for heterozygous and 0.86 (0.34 to 2.18) for homozygous C-allele carriers (Table 5). There was no evidence for a differential effect of MDM2 SNP309 by p53 tumor status on survival (Table 5).
Combined effects of TP53 R72P and MDM2 SNP309 on breast cancer survival
MDM2 SNP309 showed a differential actuarial overall survival stratified by TP53 R72P in the pooled analyses (n = 3,749), that is, homozygous carriers of the G-allele in MDM2 had worse survival within the group of TP53 GC carriers (GG: 65% versus GT: 72% and TT: 76%, P = 0.006; Figure 2). The same trend was visible in the TP53 homozygous CC group (n = 26 GG/CC), but this was not statistically significant. Within the TP53 C-allele carriers combined, MDM2 GG carriers had significantly worse survival compared to TT/TG carriers: 64% versus 75%, P = 0.001. In multivariate analyses (adjusting for study, age, stage, grade and ER) the interaction term for TP53 GC and MDM2 GG was significant (P = 0.028), also if additional interaction terms for TP53 R72P and p53 expression were included (P = 0.027). The multivariate models (adjusting for study, age, stage, grade and ER) stratified for TP53 R72P (analogue to Figure 2) showed that MDM2 GG carriers had significantly worse survival compared with MDM2 TT carriers only within the TP53 C-allele carriers; more specifically, within TP53 CG carriers: HR 1.43 (1.05 to 1.96), P = 0.02; within TP53 CC carriers HR 1.39 (0.56 to 3.48), P = 0.48 (Table 6); within TP53 CG and CC carriers combined: HR (adjusted for study, age, stage, grade and ER) 1.46 (1.09 to 1.96), P = 0.01.
Figure 2
Cumulative overall survival of breast cancer patients by MDM2 SNP309 and TP53 R72P genotypes. Each figure shows Kaplan Meier survival curves of MDM2 SNP309 genotypes within one group of TP53 R72P genotype. (a)TP53 GG genotype (ns); (b)TP53 GC genotype (P = 0.006); (c)TP53 CC genotype (ns). The numbers at start of follow-up were: Figure A: TT n = 798, TG n = 939, GG n = 281; B: TT n = 545, TG n = 698, GG n = 200; C: TT n = 110, TG n = 144, GG n = 25. Within the TP53 C-allele carriers (Figure A and B combined), MDM2 GG carriers had significantly worse survival compared to TT/TG carriers combined: 64% versus 75%, P = 0.001.
Table 6
HR estimates of multivariate analyses for MDM2 SNP309 stratified by TP53 R72P
HR
Lower and upper limit 95% CI
Pvalue
HR
Lower and upper limit 95% CI
Pvalue
HR
Lower and upper limit 95% CI
Pvalue
TP53R72P: GG
TP53R72P: GC
TP53R72P: CC
MDM2SNP309 TT
1.0 (Ref)
1.0 (Ref)
1.0 (Ref)
TG
.90
.73
1.11
.33
.94
.73
1.20
.61
.85
.47
1.55
.60
GG
.85
.63
1.16
.31
1.43
1.05
1.96
.02
1.39
.56
3.48
.48
p53 negative
1.0 (Ref)
1.0 (Ref)
1.0 (Ref)
positive
1.37
.96
1.96
.08
.89
.58
1.35
.57
.76
.25
2.30
.63
missing
1.63
1.16
2.28
.005
1.66
1.13
2.44
.009
.53
.21
1.34
.18
Stage 1
1.0 (Ref)
1.0 (Ref)
1.0 (Ref)
2
2.51
1.90
3.33
< .001
2.55
1.88
3.46
< .001
1.48
.73
2.97
.28
3
7.10
5.05
9.97
< .001
7.56
5.18
11.02
< .001
5.49
2.17
13.87
< .001
missing
3.69
2.42
5.63
< .001
2.55
1.54
4.21
< .001
1.60
.46
5.57
.46
Grade 1
1.0 (Ref)
1.0 (Ref)
1.0 (Ref)
2
1.80
1.27
2.54
.001
1.12
.77
1.62
.55
3.28
1.29
8.35
.01
3
2.63
1.84
3.76
< .001
2.39
1.65
3.46
< .001
4.08
1.55
10.79
.005
missing
1.84
1.21
2.78
.004
1.391
.87
2.22
.17
2.11
.64
6.92
.22
ER negative
1.0 (Ref)
1.0 (Ref)
1.0 (Ref)
positive
.63
.48
.84
.002
.61
.44
.83
.002
.59
.27
1.26
.17
missing
.65
.46
.91
.01
.58
.40
.84
.003
.90
.36
2.25
.82
Age
1.02
1.01
1.03
.001
1.00
.99
1.02
.54
1.01
.98
1.04
.70
Models have also been adjusted for study.
Discussion
In the survival analyses including 3,749 breast cancer patients from Finland, The Netherlands, Germany and United Kingdom, we showed combined effects of two germ-line polymorphisms, TP53 R72P, MDM2 SNP309, and p53 tumor expression (by immunohistochemistry). Firstly, we confirmed our earlier observation in Finnish patients [10] that TP53 R72P homozygous carriership predicts a worse survival in patients with p53-negative tumors, also when adjusted for clinical prognostic variables. Thus, in the absence of inactivating p53 mutations in the tumor, the 72P variant form of p53 protein may have a compromising effect on the p53 apoptotic function, leading to reduced survival of the patients. Similarly, a study of 414 Chinese breast cancer patients reported that the 72P homozygous (CC) genotype was associated with both poorer five-year overall survival (five to eight percentile difference, P = 0.04) and poorer disease-free survival among the patients with a wild-type p53 in their tumors (n = 346) [16]. In line with other studies published we did not observe an effect of carriership of R72P alone on survival of patients [12–16].
No significant difference in survival by TP53 R72P carriership was observed among the patients with p53-positive tumors, who showed a worse survival overall compared to p53-negative tumors. In the pooled analysis, CC homozygote patients with p53-positive tumors even tended to have a better survival. In the study by Xu et al. in Chinese breast cancer patients [16], the CC homozygote patients also had non-significant better survival than the GG homozygotes and heterozygotes within the group of patients with p53-mutated tumors.
The finding of CC homozygote (72P) carriers having poorer survival is consistent with the R72 variant of wild-type p53 being a more potent inducer of apoptosis than the wild-type 72P variant. It has been suggested that R72 homozygotes may respond more favorably to radiation or chemotherapy [27]. Response rate after chemo-radiotherapy of advanced squamous cell carcinomas of head and neck and survival was higher in patients with the R72 allele compared to those with the 72P allele [28]. These favorable effects of the R72 allele may, however, be reversed by a somatic p53 mutation on this allele, as has been reported in squamous cell carcinomas of head and neck [29, 30]. In line with this, retention of the R72 allele with loss of the 72P allele in the tumor tissue has been associated with reduced survival in heterozygous breast cancer patients [31].
Carriership of MDM2 SNP309 alone did not affect survival of patients in our study and two other, smaller studies [13, 22]. However, we found an 11 percentile survival difference for homozygous MDM2 G-allele carriers within the group of TP53 C-allele (72P) carriers. Biologically this seems plausible considering the reduced apoptotic function of the TP53 Pro-variant [6, 7] and the attenuation of the p53 pathway by mdm2, the production of which is increased by the SNP309 G-variant [17]. In addition, the interaction of both polymorphisms remained statistically significant in multivariate models adjusting for clinical prognostic factors.
We did not observe evidence for a combined effect of SNP309 and p53 tumor expression (as shown here by results of SNP309 stratified by p53 status in Table 5, but obviously p53 did also not have a differential effect on survival stratified by SNP309). This is in contrast to a previous, smaller study (n = 248) in the American population, which suggested that tumor p53 status was associated with breast cancer survival only among patients homozygous for the MDM2 SNP309 T-allele and not among carriers of the variant G-allele [22]. Though our study is one of the largest published studies on combined effects of the germline genetic variation and tumor somatic events, the numbers are still small for looking at such modifying effects on survival.
Many studies have confirmed that mutated p53 is a prognostic factor in breast cancer. The risk of dying of breast cancer for patients with a p53 mutation in their tumor has been estimated to be two to five-fold compared to patients with wild-type p53 tumors [32, 33]. Positive immunostaining for p53 is in general considered to indicate somatic p53 mutation and an impaired p53 pathway, though the correlation with TP53 mutations is incomplete [34, 35]. The accumulation of p53 in the tumors detected by immunohistochemistry was a prognostic marker of poorer survival in both our series with p53 immunohistochemistry data available (the HEBCS and ABCS series). This effect was somewhat stronger in the HEBCS series, which may be explained by the more stringent cut-off used (20% positive tumor cells compared to 10% in the ABCS series).
Conclusions
We have shown here that TP53 R72P may have additional prognostic value especially among patients with p53-negative tumors. However, the effect of p53 on outcome may be influenced by adjuvant systemic therapy (for example, [31, 36], reviewed in Bertheau [37]) and larger studies will be needed to address this question. Our study is one of the few that have shown an interaction of germ-line variants, that is, TP53 R72P and MDM2 SNP309, in breast cancer survival. The results, showing a statistically significant interaction of the p53 Pro-variant and the GG genotype of MDM2 SNP309, are in line with our a priori biologically-supported hypothesis, which is, the role of enhanced DNA repair function of the Pro-variant, combined with increased expression of the Mdm2 protein, and thus overall attenuation of the p53 pathway in the tumor cells. These results suggest that even subtle differences in p53 apoptotic function caused by synergistic polymorphisms may affect patient's survival, possibly by modifying treatment response. Altogether, our findings are in line with biological evidence in literature, and in the future, may have also clinical significance for models of breast cancer prognosis or treatment. However, because this is the first report on the combined effect of TP53 R72P and MDM2 SNP309 on breast cancer survival and we cannot exclude a chance finding, other studies to confirm this will be necessary. Larger studies will be needed also to investigate the effect of specific treatment modalities on the survival by TP53 R72P and MDM2 SNP309.
Abbreviations
ABCS:
Amsterdam Breast Cancer Study
ER:
estrogen receptor
HABCS:
Hannover Breast Cancer Study
HEBCS:
Helsinki Breast Cancer Study
HR:
hazard ratio
SD:
standard deviation
SEARCH:
Studies of Epidemiology and Risk Factors in Cancer Heredity
TMA:
tissue micro array.
Declarations
Acknowledgements
We wish to thank Dr Hannaleena Eerola and Dr Kirsimari Aaltonen and Nina Puolakka RN for their help with the Finnish patient data. The Finnish Cancer registry is gratefully acknowledged for the cancer data. The Helsinki study has been financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (110663), Finnish Cancer Society, the Sigrid Juselius Foundation, and the Ida Montin Foundation. We highly appreciate the contributions of our Dutch colleagues at the NKI-AVL, among others Renate Udo, Linde Braaf and Hans Peterse†; and at LUMC: Rob Tollenaar, Vincent Smit and Cees Cornelisse; the Dutch study was financed by the Dutch Cancer Society (NKI 2001-2423; 2007-3839) and the Cancer Genomics Center (Dutch Genomics Initiative). We are grateful to our German colleagues Michael Bremer, Andreas Meyer, Johann H. Karstens and Peter Hillemanns for their support of the study at Hannover Medical School. The SEARCH study is funded by Cancer Research UK, and DFE is a Principal Research Fellow and PDP is a Senior Clinical Research Fellow of CRUK.
Authors’ Affiliations
(1)
Departments of Epidemiology, Experimental Therapy and Pathology, Netherlands Cancer Institute, The Netherlands
(2)
Department of Obstetrics and Gynecology, Helsinki University Central Hospital (HUCH)
(3)
Strangeway's Research Laboratory, Worts Causeway
(4)
Hannover Medical School, Departments of Gynaecology and Radiation Oncology
(5)
Department of Oncology, Helsinki University Central Hospital (HUCH)
References
Schmidt MK, Reincke S, Broeks A, Braaf LM, Hogervorst FBL, Tollenaar RAEM, Johnson N, Fletcher O, Peto J, Tommiska J, Blomqvist C, Nevanlinna HA, Healey CS, Dunning AM, Pharoah PD, Easton DF, Dork T, Van't Veer LJ, on behalf of the Breast Cancer Association Consortium: Do MDM2 SNP309 and TP53 R72P Interact in Breast Cancer Susceptibility? A Large Pooled Series from the Breast Cancer Association Consortium. Cancer Res. 2007, 67: 9584-9590. 10.1158/0008-5472.CAN-07-0738.View ArticlePubMedGoogle Scholar
Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrjakoski K, Kallioniemi A, Kilpivaara O, Mannermaa A, Kosma VM, Uusitupa M, Eskelinen M, Kataja V, Aittomaki K, von Smitten K, Heikkila P, Lukas J, Holli K, Bartkova J, Blomqvist C, Bartek J, Nevanlinna H: NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet. 2008, 40: 844-853. 10.1038/ng.155.View ArticlePubMedGoogle Scholar
Bond GL, Hu W, Levine AJ: MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets. 2005, 5: 3-8. 10.2174/1568009053332627.View ArticlePubMedGoogle Scholar
Walker KK, Levine AJ: Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci USA. 1996, 93: 15335-15340. 10.1073/pnas.93.26.15335.View ArticlePubMedPubMed CentralGoogle Scholar
Sakamuro D, Sabbatini P, White E, Prendergast GC: The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene. 1997, 15: 887-898. 10.1038/sj.onc.1201263.View ArticlePubMedGoogle Scholar
Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G: Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999, 19: 1092-1100.View ArticlePubMedPubMed CentralGoogle Scholar
Pim D, Banks L: p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer. 2004, 108: 196-199. 10.1002/ijc.11548.View ArticlePubMedGoogle Scholar
Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, Bisso A, Del Sal G, Syed N, Smith P, Gasco M, Crook T, Lu X: iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet. 2006, 38: 1133-1141. 10.1038/ng1879.View ArticlePubMedGoogle Scholar
Siddique MM, Balram C, Fiszer-Maliszewska L, Aggarwal A, Tan A, Tan P, Soo KC, Sabapathy K: Evidence for selective expression of the p53 codon 72 polymorphs: implications in cancer development. Cancer Epidemiol Biomarkers Prev. 2005, 14: 2245-2252. 10.1158/1055-9965.EPI-05-0153.View ArticlePubMedGoogle Scholar
Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, Ristimaki A, von Smitten K, Aittomaki K, Heikkila P, Blomqvist C, Nevanlinna H: Breast Cancer Patients with p53 Pro72 Homozygous Genotype Have a Poorer Survival. Clin Cancer Res. 2005, 11: 5098-5103. 10.1158/1078-0432.CCR-05-0173.View ArticlePubMedGoogle Scholar
The Breast Cancer Association Consortium: Commonly Studied Single-Nucleotide Polymorphisms and Breast Cancer: Results From the Breast Cancer Association Consortium. J Natl Cancer Inst. 2006, 98: 1382-1396.View ArticleGoogle Scholar
Goode E, Dunning A, Kuschel B, Healey C, Day N, Ponder B, Easton D, Pharoah P: Effect of Germ-Line Genetic Variation on Breast Cancer Survival in a Population-based Study. Cancer Res. 2002, 62: 3052-3057.PubMedGoogle Scholar
Toyama T, Zhang Z, Nishio M, Hamaguchi M, Kondo N, Iwase H, Iwata H, Takahashi S, Yamashita H, Fujii Y: Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res. 2007, 9: R34-10.1186/bcr1682.View ArticlePubMedPubMed CentralGoogle Scholar
Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z, Lin B, Lu Y, Xie Y: p53 Codon 72 Polymorphism Predicts the Pathologic Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer. Clin Cancer Res. 2005, 11: 7328-7333. 10.1158/1078-0432.CCR-05-0507.View ArticlePubMedGoogle Scholar
Kyndi M, Alsner J, Hansen LL, Sorensen FB, Overgaard J: LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer. Acta Oncol. 2006, 45: 602-609. 10.1080/02841860600660811.View ArticlePubMedGoogle Scholar
Xu Y, Yao L, Zhao A, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Lu Y, Xie Y: Effect of p53 codon 72 genotype on breast cancer survival depends on p53 gene status. Int J Cancer. 2008, 122: 2761-2766. 10.1002/ijc.23454.View ArticlePubMedGoogle Scholar
Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004, 119: 591-602. 10.1016/j.cell.2004.11.022.View ArticlePubMedGoogle Scholar
Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, Chompret A, Bressac-de Paillerets B, Stoppa-Lyonnet D, Bonaiti-Pellie C, Frebourg T: Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet. 2006, 43: 531-533. 10.1136/jmg.2005.037952.View ArticlePubMedGoogle Scholar
Ruijs MWG, Schmidt MK, Nevanlinna H, Tommiska J, Aittomäki K, Pruntel R, Verhoef S, Van't Veer LJ: The single nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet. 2007, 15: 110-114. 10.1038/sj.ejhg.5201715.View ArticlePubMedGoogle Scholar
Wasielewski M, Nagel JH, Brekelmans C, Klijn JG, Ouweland van den A, Meijers-Heijboer H, Schutte M: MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling. Breast Cancer Res Treat. 2006, 104: 153-175. 10.1007/s10549-006-9407-5.View ArticlePubMedGoogle Scholar
Cox DG, Deer D, Guo Q, Tworoger SS, Hankinson SE, Hunter DJ, De Vivo I: The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses' health studies. Cancer Causes Control. 2007, 18: 621-625. 10.1007/s10552-007-9004-x.View ArticlePubMedGoogle Scholar
Boersma B, Howe T, Goodman J, Yfantis H, Lee D, Chanock S, Ambs S: Association of Breast Cancer Outcome With Status of p53 and MDM2 SNP309. J Natl Cancer Inst. 2006, 98: 911-919.View ArticlePubMedGoogle Scholar
Gryshchenko I, Hofbauer S, Stoecher M, Daniel P, Steurer M, Gaiger A, Eigenberger K, Greil R, Tinhofer I: MDM2 SNP309 Is Associated With Poor Outcome in B-Cell Chronic Lymphocytic Leukemia. J Clin Oncol. 2008, 26: 2252-2257. 10.1200/JCO.2007.11.5212.View ArticlePubMedGoogle Scholar
Nechushtan H, Hamburger T, Mendelson S, Kadouri L, Sharon N, Pikarsky E, Peretz T: Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations. BMC Cancer. 2009, 9: 60-10.1186/1471-2407-9-60.View ArticlePubMedPubMed CentralGoogle Scholar
Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, Bojesen SE, Nordestgaard BG, Axelsson CK, Arias JI, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Zamora P, Brauch H, Justenhoven C, Hamann U, Ko YD, Bruening T, Haas S, Dork T, Schurmann P, Hillemanns P, Bogdanova N, Bremer M, Karstens JH, Fagerholm R, Aaltonen K, Aittomaki K: Heterogeneity of breast cancer associations with five susceptibility Loci by clinical and pathological characteristics. PLoS Genet. 2008, 4: e1000054-10.1371/journal.pgen.1000054.View ArticlePubMedPubMed CentralGoogle Scholar
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005, 23: 9067-9072. 10.1200/JCO.2004.01.0454.View ArticlePubMedGoogle Scholar
Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003, 33: 357-365. 10.1038/ng1093.View ArticlePubMedGoogle Scholar
Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, Attard M, Hiller L, Farrell PJ, Smith P, Lu X, Crook T: Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene. 2004, 23: 3328-3337. 10.1038/sj.onc.1207428.View ArticlePubMedGoogle Scholar
Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farrell PJ, Smith P, Lu X, Crook T: p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell. 2003, 3: 387-402. 10.1016/S1535-6108(03)00079-5.View ArticlePubMedGoogle Scholar
Schneider-Stock R, Mawrin C, Motsch C, Boltze C, Peters B, Hartig R, Buhtz P, Giers A, Rohrbeck A, Freigang B, Roessner A: Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. Am J Pathol. 2004, 164: 1233-1241.View ArticlePubMedPubMed CentralGoogle Scholar
Bonafe M, Ceccarelli C, Farabegoli F, Santini D, Taffurelli M, Barbi C, Marzi E, Trapassi C, Storci G, Olivieri F, Franceschi C: Retention of the p53 Codon 72 Arginine Allele Is Associated with a Reduction of Disease-Free and Overall Survival in Arginine/Proline Heterozygous Breast Cancer Patients. Clin Cancer Res. 2003, 9: 4860-4864.PubMedGoogle Scholar
Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bieche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Borresen-Dale A: The Clinical Value of Somatic TP53 Gene Mutations in 1,794 Patients with Breast Cancer. Clin Cancer Res. 2006, 12: 1157-1167. 10.1158/1078-0432.CCR-05-1029.View ArticlePubMedGoogle Scholar
Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M: TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007, 26: 2157-2165. 10.1038/sj.onc.1210302.View ArticlePubMedGoogle Scholar
Soussi T, Beroud C: Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 2001, 1: 233-240. 10.1038/35106009.View ArticlePubMedGoogle Scholar
Sjogren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L, Bergh J: The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst. 1996, 88: 173-182. 10.1093/jnci/88.3-4.173.View ArticlePubMedGoogle Scholar
Bidard FC, Matthieu MC, Chollet P, Raoefils I, Abrial C, Domont J, Spielmann M, Delaloge S, Andre F, Penault-Llorca F: p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. Ann Oncol. 2008, 19: 1261-1265. 10.1093/annonc/mdn039.View ArticlePubMedGoogle Scholar
Bertheau P, Espie M, Turpin E, Lehmann J, Plassa LF, Varna M, Janin A, de The H: TP53 status and response to chemotherapy in breast cancer. Pathobiology. 2008, 75: 132-139. 10.1159/000123851.View ArticlePubMedGoogle Scholar
Schmidt MK, Tollenaar RAEM, de Kemp SR, Broeks A, Cornelisse CJ, Smit VTHBM, Peterse JL, van Leeuwen FE, Van't Veer LJ: Breast Cancer Survival and Tumor Characteristics in Premenopausal Women Carrying the CHEK2*1100delC Germline Mutation. J Clin Oncol. 2007, 25: 64-69. 10.1200/JCO.2006.06.3024.View ArticlePubMedGoogle Scholar
Steinmann D, Bremer M, Rades D, Skawran B, Siebrands C, Karstens JH, Dork T: Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer. Br J Cancer. 2001, 85: 850-858. 10.1054/bjoc.2001.2016.View ArticlePubMedPubMed CentralGoogle Scholar
Dork T, Bendix R, Bremer M, Rades D, Klopper K, Nicke M, Skawran B, Hector A, Yamini P, Steinmann D, Weise S, Stuhrmann M, Karstens JH: Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. Cancer Res. 2001, 61: 7608-7615.PubMedGoogle Scholar
Syrjakoski K, Vahteristo P, Eerola H, Tamminen A, Kivinummi K, Sarantaus L, Holli K, Blomqvist C, Kallioniemi OP, Kainu T, Nevanlinna H: Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst. 2000, 92: 1529-1531. 10.1093/jnci/92.18.1529.View ArticlePubMedGoogle Scholar
Cebrian A, Pharoah P, Ahmed S, Ropero S, Fraga M, Smith P, Conroy D, Luben R, Perkins B, Easton D, Dunning A, Esteller M, Ponder B: Genetic variants in epigenetic genes and breast cancer risk. Carcinogenesis. 2006, 27: 1661-1669. 10.1093/carcin/bgi375.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
